Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Antonio Vitale, Valeria Caggiano, Virginia Berlengiero, Maria Orsetta Perfetti, Jurgen Sota, Gian Marco Tosi, Bruno Frediani, Luca Cantarini & Claudia Fabiani. (2023) Comparing biologic options for the management of Behcet’s disease-related uveitis. Expert Review of Clinical Immunology 19:3, pages 315-328.
Read now
Read now
Shivam H. Patel, Aditya Belamkar, Amir R. Hajrasouliha, Denis Jusufbegovic & Thomas A. Ciulla. (2022) Progress in the pharmacotherapy of uveitis: the art of personalized care. Expert Opinion on Pharmacotherapy 23:12, pages 1445-1455.
Read now
Read now
Luca De Simone, Alessandro Invernizzi, Raffaella Aldigeri, Valentina Mastrofilippo, Chiara Marvisi, Fabrizio Gozzi, Elena Bolletta, Chantal Adani, Nicolò Pipitone, Francesco Muratore, Luigi Fontana, Carlo Salvarani & Luca Cimino. (2022) Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features. Ocular Immunology and Inflammation 30:2, pages 506-514.
Read now
Read now
Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini & Florenzo Iannone. (2020) Safety of systemic treatments for Behçet’s syndrome. Expert Opinion on Drug Safety 19:10, pages 1269-1301.
Read now
Read now
Ilknur Tugal-Tutkun & Pinar Çakar Özdal. (2020) Behçet’s disease uveitis: is there a need for new emerging drugs?. Expert Opinion on Emerging Drugs 25:4, pages 531-547.
Read now
Read now
Carla Gaggiano, Jurgen Sota, Stefano Gentileschi, Valeria Caggiano, Salvatore Grosso, Gian Marco Tosi, Bruno Frediani, Luca Cantarini & Claudia Fabiani. (2020) The current status of biological treatment for uveitis. Expert Review of Clinical Immunology 16:8, pages 787-811.
Read now
Read now
Uwe Pleyer, Dominika Pohlmann, Esra Kardeş, Denis Poddubnyy & Judith Rademacher. (2019) Emerging drugs for the treatment of noninfectious uveitis. Expert Opinion on Emerging Drugs 24:3, pages 173-190.
Read now
Read now
Articles from other publishers (16)
Desmond Patrick Kidd. (2023) Neurological involvement by Behçet’s syndrome: clinical features, diagnosis, treatment and outcome. Practical Neurology 23:5, pages 386-400.
Crossref
Crossref
Masaru Takeuchi, Yoshihiko Usui, Kenichi Namba, Hiroshi Keino, Masaki Takeuchi, Hiroshi Takase, Koju Kamoi, Keitaro Hase, Takako Ito, Kei Nakai, Kazuichi Maruyama, Eri Kobayashi, Hisashi Mashimo, Tomohito Sato, Nobuyuki Ohguro, Junko Hori, Annabelle A. Okada, Koh-hei Sonoda, Nobuhisa Mizuki & Hiroshi Goto. (2023) Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study. Frontiers in Medicine 10.
Crossref
Crossref
F. Alizadegan, O. Yalcinbayir, G. Ucan Gunduz & Y. Pehlivan. (2022) Infliximab therapy in Behçet's uveitis. Journal Français d'Ophtalmologie 45:9, pages 1036-1041.
Crossref
Crossref
Xinwei Zhou, Xianghui Shi, Yanxia Ren, Tingting Yan & Qiao Ye. (2022) Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behçet’s disease: A systematic review of controlled trials. Frontiers in Pharmacology 13.
Crossref
Crossref
Bowen Li, Li Yang, Feng Bai, Bainan Tong & Xiaoli Liu. (2022) Indications and effects of biological agents in the treatment of noninfectious uveitis. Immunotherapy 14:12, pages 985-994.
Crossref
Crossref
Simple GuptaK. ShyamsundarMohini Agrawal, Nitin VichareJyotirmay Biswas. (2022) Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics 38:3, pages 203-222.
Crossref
Crossref
Jingjing Chen & Xu Yao. (2021) A Contemporary Review of Behcet’s Syndrome. Clinical Reviews in Allergy & Immunology 61:3, pages 363-376.
Crossref
Crossref
Hanna Zając & Anna Turno-Kręcicka. (2021) Ocular Manifestations of Behçet’s Disease: An Update on Diagnostic Challenges and Disease Management. Journal of Clinical Medicine 10:21, pages 5174.
Crossref
Crossref
Anji Xiong, Deng Liu, Huini Chen, Guancui Yang, Chen Xiong, Yu Shuai, Linqian He, Zepeng Guo, Liangwen Zhang, Yuan Yang, Beibei Cui & Shiquan Shuai. (2021) The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies. Frontiers in Pharmacology 12.
Crossref
Crossref
Shizhao Yang, Zhaohao Huang, Yunwei Hu, Jian Zhang, Xiuxing Liu, He Li, Lihui Xie, Feng Wen, Dan Liang & Wenru Su. (2021) The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet’s Retinal Vasculitis. Frontiers in Pharmacology 12.
Crossref
Crossref
Fatma Alibaz-Oner & Haner Direskeneli. (2021) Advances in the Treatment of Behcet’s Disease. Current Rheumatology Reports 23:6.
Crossref
Crossref
Gamze Ucan GunduzOzgur YalcinbayirSukru CekicMeral YildizSara S. Kilic. (2021) Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab. Journal of Ocular Pharmacology and Therapeutics 37:4, pages 236-240.
Crossref
Crossref
Thomas El Jammal, Olivier Loria, Yvan Jamilloux, Mathieu Gerfaud-Valentin, Laurent Kodjikian & Pascal Sève. (2021) Uveitis as an Open Window to Systemic Inflammatory Diseases. Journal of Clinical Medicine 10:2, pages 281.
Crossref
Crossref
Yunwei Hu, Zhaohao Huang, Shizhao Yang, Xiaoqing Chen, Wenru Su & Dan Liang. (2020) Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 11.
Crossref
Crossref
. (2020) Infliximab/interferon-alpha-2a. Reactions Weekly 1802:1, pages 162-162.
Crossref
Crossref
H. Nida Sen. 2020. Whitcup and Nussenblatt's Uveitis. Whitcup and Nussenblatt's Uveitis
326
349
.